Abstract 174P
Background
Colorectal cancer (CRC) is the second leading cause of cancer deaths, and liver metastasis accounts for most fatalities in CRC patients. Developing more effective treatments for patients with metastatic CRC is an urgent unmet need. Sphingosine kinase 1 (SPHK1) is selectively expressed in tumor-associated macrophages (TAMs) and SPHK1+ TAMs are abundant in metastatic tumor microenvironment. Here, we aimed to reveal the role of SPHK1+ TAMs in regulating immunosuppression and develop novel therapeutic strategies to enhance the efficacy of immune checkpoint blockade (ICB) therapy and mitigate ICB-induced toxicity.
Methods
The expression of SPHK1 in TAMs was determined using laser scanning microscopy and single-cell sequencing databases. The inhibitory effect of SPHK1 blockade alone or combined with ICB on liver metastasis was assessed using an orthotopic mouse model or intrasplenic injection of tumor cells. Flow cytometry and mass cytometry were used to analyze the immune microenvironment in SPHK1-/- knockout mice. The effect of SPHK1 inhibitor PF543 on the ICB-induced toxicity was verified by DSS-induced colitis or humanized mouse model in a combination of ICB. RNA sequencing and western blot were used to further explore the molecular mechanism by which SPHK1 promoted inflammasome activation and IL-1β release.
Results
SPHK1 was selectively expressed by TAMs in CRC, and the abundance of SPHK1+ TAMs was associated with adverse clinical outcomes in CRC patients. In vivo, SPHK1 knockout and inhibition suppressed liver metastasis of CRC and enhanced the anti-tumor activity of ICB. Blocking SPHK1 reduced the infiltration of TAMs and exhausted T cells, and promoted cytotoxicity of CD8+ T cells. Mechanistically, SPHK1/S1P axis led to IL-1β secretion in response to AIM2 and NLRP3 inflammasome activation. SPHK1 inhibitor PF543 and anti-IL-1R alleviated ICB-induced toxicity, including colitis and liver damage. PF543 plus anti-PD-1 therapy could induce complete regression of liver metastasis and mitigate liver dysfunction when further combined with radiotherapy.
Conclusions
Targeting SPHK1 in macrophages could inhibit liver metastasis of CRC and decouple ICB anti-tumor immunity and toxicity.
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (No.82103595).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
46P - Immunoprofiling of Peripheral Blood Cells as a Potential Predictor of Immune-Related Toxicity of PD-1 Inhibitors
Presenter: Jan Podhorec
Session: Poster Display
47TiP - A real-world study of multiparametric prediction of the efficacy of immune checkpoint inhibitors in combination with chemotherapy for advanced non-small cell lung cancer
Presenter: Zihan Zhou
Session: Poster Display
51P - Phase 1B (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): preliminary results
Presenter: Laura Ridolfi
Session: Poster Display
52P - The dependence of TKI-resistant lung cancer cells on EGFR increases sensitivity to EGFR-CAR NK.
Presenter: Sumei Chen
Session: Poster Display
53P - Integrin-_v_6 targeted CAR T-cells in an immunocompetent orthotopic model of pancreatic cancer
Presenter: Nicholas Brown
Session: Poster Display
55P - DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex
Presenter: wei zhang
Session: Poster Display
56P - FOXM1D in T cells promotes the transcription of PD-1 by interacting with HCFC1 and regulating the killing of renal cancer cells
Presenter: yue wang
Session: Poster Display
57P - Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL)
Presenter: Joachim Stoltenborg Granhøj
Session: Poster Display
58P - Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
Presenter: Liangping Li
Session: Poster Display
59P - Revolutionizing cell therapy testing by co-culturing 3D patient derived cancer models and circulating immune cells on Organ-on-chip platform
Presenter: silvia Scaglione
Session: Poster Display